OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Synthesis and biological evaluation of halogenated phenoxychalcones and their corresponding pyrazolines as cytotoxic agents in human breast cancer
Peter A. Halim, Rasha A. Hassan, Khaled O. Mohamed, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2021) Vol. 37, Iss. 1, pp. 189-201
Open Access | Times Cited: 20
Peter A. Halim, Rasha A. Hassan, Khaled O. Mohamed, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2021) Vol. 37, Iss. 1, pp. 189-201
Open Access | Times Cited: 20
Showing 20 citing articles:
Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction
Mohamed T. M. Nemr, Ahmed Elshewy, Mohammed L. Ibrahim, et al.
Bioorganic Chemistry (2024) Vol. 150, pp. 107566-107566
Closed Access | Times Cited: 9
Mohamed T. M. Nemr, Ahmed Elshewy, Mohammed L. Ibrahim, et al.
Bioorganic Chemistry (2024) Vol. 150, pp. 107566-107566
Closed Access | Times Cited: 9
New oxadiazole and pyrazoline derivatives as anti-proliferative agents targeting EGFR-TK: design, synthesis, biological evaluation and molecular docking study
Marwa I. Serag, Samar S. Tawfik, Sahar Badr, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Marwa I. Serag, Samar S. Tawfik, Sahar Badr, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Coumarin derivatives with potential anticancer and antibacterial activity: Design, synthesis, VEGFR‐2 and DNA gyrase inhibition, and in silico studies
Soha H. Emam, Rasha A. Hassan, Eman O. Osman, et al.
Drug Development Research (2023) Vol. 84, Iss. 3, pp. 475-499
Closed Access | Times Cited: 17
Soha H. Emam, Rasha A. Hassan, Eman O. Osman, et al.
Drug Development Research (2023) Vol. 84, Iss. 3, pp. 475-499
Closed Access | Times Cited: 17
Design, Synthesis, and Molecular Docking of Novel Miscellaneous Chalcones as p38α Mitogen‐Activated Protein Kinase Inhibitors
Mai M. Zeid, Osama M. El‐Badry, Salwa Elmeligie, et al.
Chemistry & Biodiversity (2024) Vol. 21, Iss. 4
Closed Access | Times Cited: 5
Mai M. Zeid, Osama M. El‐Badry, Salwa Elmeligie, et al.
Chemistry & Biodiversity (2024) Vol. 21, Iss. 4
Closed Access | Times Cited: 5
New thienopyrimidine-based derivatives: Design, synthesis, and biological evaluation as potent anticancer agents and VEGFR-2 inhibitors
Myrna A. Farag, Manal M. Kandeel, Asmaa E. Kassab, et al.
Journal of Molecular Structure (2025) Vol. 1334, pp. 141884-141884
Closed Access
Myrna A. Farag, Manal M. Kandeel, Asmaa E. Kassab, et al.
Journal of Molecular Structure (2025) Vol. 1334, pp. 141884-141884
Closed Access
Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition
Peter A. Halim, Souty M.Z. Sharkawi, Madlen B. Labib
Bioorganic Chemistry (2022) Vol. 131, pp. 106273-106273
Closed Access | Times Cited: 25
Peter A. Halim, Souty M.Z. Sharkawi, Madlen B. Labib
Bioorganic Chemistry (2022) Vol. 131, pp. 106273-106273
Closed Access | Times Cited: 25
Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3‐d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR‐2 inhibition, and down‐regulation of PI3K/AKT/mTOR signaling pathway
Safaa E. Seif, Zeinab Mahmoud, Wagnat W. Wardakhan, et al.
Drug Development Research (2023) Vol. 84, Iss. 5, pp. 839-860
Closed Access | Times Cited: 13
Safaa E. Seif, Zeinab Mahmoud, Wagnat W. Wardakhan, et al.
Drug Development Research (2023) Vol. 84, Iss. 5, pp. 839-860
Closed Access | Times Cited: 13
Design, synthesis, anticancer, and antibacterial evaluation of some quinazolinone‐based derivatives as DHFR inhibitors
Eman O. Osman, Soha H. Emam, Amr Sonousi, et al.
Drug Development Research (2023) Vol. 84, Iss. 5, pp. 888-906
Closed Access | Times Cited: 13
Eman O. Osman, Soha H. Emam, Amr Sonousi, et al.
Drug Development Research (2023) Vol. 84, Iss. 5, pp. 888-906
Closed Access | Times Cited: 13
m6A Modification Mediates Exosomal LINC00657 to Trigger Breast Cancer Progression Via Inducing Macrophage M2 Polarization
Jiafeng Chen, Yuxin Zhou, Minhua Wu, et al.
Clinical Breast Cancer (2023) Vol. 23, Iss. 5, pp. 546-560
Closed Access | Times Cited: 13
Jiafeng Chen, Yuxin Zhou, Minhua Wu, et al.
Clinical Breast Cancer (2023) Vol. 23, Iss. 5, pp. 546-560
Closed Access | Times Cited: 13
Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights
Tarfah Al‐Warhi, Ahmed M. El Kerdawy, Mohamed A. Said, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1457-1471
Open Access | Times Cited: 20
Tarfah Al‐Warhi, Ahmed M. El Kerdawy, Mohamed A. Said, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1457-1471
Open Access | Times Cited: 20
Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking
Rasha A. Hassan, Maha M. Abdel‐Fattah, Amr M. Abdou, et al.
Bioorganic Chemistry (2022) Vol. 125, pp. 105861-105861
Open Access | Times Cited: 19
Rasha A. Hassan, Maha M. Abdel‐Fattah, Amr M. Abdou, et al.
Bioorganic Chemistry (2022) Vol. 125, pp. 105861-105861
Open Access | Times Cited: 19
Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity
Amr Sonousi, Rasha A. Hassan, Eman O. Osman, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 2644-2659
Open Access | Times Cited: 17
Amr Sonousi, Rasha A. Hassan, Eman O. Osman, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 2644-2659
Open Access | Times Cited: 17
Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3‐d]pyrimidine derivatives as EGFR inhibitors
Menna Tallah M. Sayed, Peter A. Halim, Afaf K. El‐Ansary, et al.
Drug Development Research (2023) Vol. 84, Iss. 6, pp. 1299-1319
Closed Access | Times Cited: 8
Menna Tallah M. Sayed, Peter A. Halim, Afaf K. El‐Ansary, et al.
Drug Development Research (2023) Vol. 84, Iss. 6, pp. 1299-1319
Closed Access | Times Cited: 8
Novel pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, anticancer evaluation, VEGFR-2 inhibition, and antiangiogenic activity
Ahmed M. Abdelhamed, Rasha A. Hassan, Hanan H. Kadry, et al.
RSC Medicinal Chemistry (2023) Vol. 14, Iss. 12, pp. 2640-2657
Open Access | Times Cited: 6
Ahmed M. Abdelhamed, Rasha A. Hassan, Hanan H. Kadry, et al.
RSC Medicinal Chemistry (2023) Vol. 14, Iss. 12, pp. 2640-2657
Open Access | Times Cited: 6
New S‐substituted‐3‐phenyltetrahydrobenzo[4,5]thieno[2,3‐d]pyrimidin‐4(3H)‐one scaffold with promising anticancer activity profile through the regulation and inhibition of mutated B‐RAF signaling pathway
Safaa E. Seif, Wagnat W. Wardakhan, Rasha A. Hassan, et al.
Drug Development Research (2024) Vol. 85, Iss. 7
Open Access | Times Cited: 1
Safaa E. Seif, Wagnat W. Wardakhan, Rasha A. Hassan, et al.
Drug Development Research (2024) Vol. 85, Iss. 7
Open Access | Times Cited: 1
Targeting autophagy with tamoxifen in breast cancer: From molecular mechanisms to targeted therapy
Mohammad Yasin Zamanian, Maryam Golmohammadi, Amir Nili‐Ahmadabadi, et al.
Fundamental and Clinical Pharmacology (2023) Vol. 37, Iss. 6, pp. 1092-1108
Closed Access | Times Cited: 4
Mohammad Yasin Zamanian, Maryam Golmohammadi, Amir Nili‐Ahmadabadi, et al.
Fundamental and Clinical Pharmacology (2023) Vol. 37, Iss. 6, pp. 1092-1108
Closed Access | Times Cited: 4
Design, Synthesis, Crystal Structure, Biological Activity and Molecular Modeling of Novel Schiff Bases Derived from Chalcones and 5-Hydrazino-1,3-Dimethyl-4-Nitropyrazole as Anticancer Agents
Majed Shtaiwi, Mohammad Alemleh, Kayed A. Abu Safieh, et al.
Polycyclic aromatic compounds (2023) Vol. 44, Iss. 6, pp. 4178-4196
Closed Access | Times Cited: 4
Majed Shtaiwi, Mohammad Alemleh, Kayed A. Abu Safieh, et al.
Polycyclic aromatic compounds (2023) Vol. 44, Iss. 6, pp. 4178-4196
Closed Access | Times Cited: 4
Exploring the copper(II) coordination to 2′-hydroxy-4-benzyloxychalcone analogues and their potential pharmacological applications
Laiane dos Santos Oliveira, Pedro Henrique de Souza Guarda, Letícia B. Rosa, et al.
Inorganica Chimica Acta (2023) Vol. 560, pp. 121806-121806
Closed Access | Times Cited: 1
Laiane dos Santos Oliveira, Pedro Henrique de Souza Guarda, Letícia B. Rosa, et al.
Inorganica Chimica Acta (2023) Vol. 560, pp. 121806-121806
Closed Access | Times Cited: 1
Chemistry and synthetic methodologies of chalcones and their derivatives: A review
Praveen Sekar, Shridharshini Kumar, Raju Senthil Kumar
International Journal of Biological and Pharmaceutical Sciences Archive (2023) Vol. 5, Iss. 1, pp. 051-072
Open Access
Praveen Sekar, Shridharshini Kumar, Raju Senthil Kumar
International Journal of Biological and Pharmaceutical Sciences Archive (2023) Vol. 5, Iss. 1, pp. 051-072
Open Access
An Updated Review on Recent Advancements in the Diverse Biological Applications of Medicinally Privileged Scaffold: Chalcone and its derivatives
Praveen Sekar, Shridharshini Kumar, Raju Senthil Kumar
International Journal of Medical Sciences and Pharma Research (2023) Vol. 9, Iss. 1, pp. 7-20
Open Access
Praveen Sekar, Shridharshini Kumar, Raju Senthil Kumar
International Journal of Medical Sciences and Pharma Research (2023) Vol. 9, Iss. 1, pp. 7-20
Open Access
